Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.

Journal of medical genetics - 1 Jul 2012

Schulz Eduard, Valentin Angelika, Ulz Peter, Beham-Schmid Christine, Lind Karin, Rupp Verena, Lackner Herwig, Wölfler Albert, Zebisch Armin, Olipitz Werner, Geigl Jochen, Berghold Andrea, Speicher Michael R, Sill Heinz

Abstract excerpt

BACKGROUND: Therapy related myeloid neoplasms (t-MNs) are complex diseases originating from an interplay between exogenous toxicities and a susceptible organism. It has been hypothesised that in a subset of cases t-MNs develop in the context of hereditary cancer predisposition syndromes. METHODS: The study systematically evaluated pedigrees of patients with t-MNs for cancer incidences and the possibility of a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Damage

Share to Germ-Line Mutation

Share to Hereditary Breast and Ovarian Cancer Syndrome

Share to Neoplasms, Second Primary

Share to Tumor Suppressor Proteins

Share to Ubiquitin-Protein Ligases

Source

Identifiers

PMID: 22652532
DOI: 10.1136/jmedgenet-2011-100674

Genes

BARD1
BRCA1
BRCA2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.PMID 22652532Read ↗

Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms.Semantic proximity Read ↗

Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.Semantic proximity Read ↗

What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms.Semantic proximity Read ↗

Fanconi anemia gene variants in therapy-related myeloid neoplasmsSemantic proximity Read ↗

Therapy-related myeloid neoplasms: what's in a name?Semantic proximity Read ↗

Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants.Semantic proximity Read ↗

<i>TP53</i>mutation screening for patients at risk of myeloid malignancySemantic proximity Read ↗

Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?Semantic proximity Read ↗

Identification of methylguanine methyltransferase polymorphisms as genetic markers of individual susceptibility to therapy-related myeloid neoplasms.Semantic proximity Read ↗

Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1.Semantic proximity Read ↗

Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype.Semantic proximity Read ↗

Influence of DNA damage and repair upon the risk of treatment related leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.